Crowdonomics
All companies

Pharmagreen Biotech Inc.

Public

Transportation · Coquitlam

Estimated pre-money ⓘ
$10.4M
As of Apr 2021 · from Reg A Offering (2021) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2021
Latest share price
$0.03
Reg A Offering (2021) offering price

Financials

FY2018–FY2022 · from SEC filings · hover any figure for its source
−$1.1M
2018
−$768K
2019
$0
−$2.4M
2020
−$4.5M
2021
−$876K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 audited
FY2019 audited
FY2020 audited
FY2021 audited
FY2022 audited
Income statement
Revenue
—
—
$0
—
—
Cost of goods sold
—
—
$3,769,058
—
—
Net income
-$1,073,581
-$767,537
-$2,437,870
-$4,532,224
-$875,505
Taxes paid
—
—
$0
$0
$0
Balance sheet
Cash
$151,869
$62,682
$12,196
$25,300
$8,016
Accounts receivable
—
—
$0
—
—
Total assets
$449,420
$630,272
$266,245
$373,081
$208,971
Long-term debt
—
—
$30,028
—
—
Total liabilities
$1,836,881
$1,464,770
$3,200,350
$2,065,781
$2,031,620
Other
Headcount
—
—
0
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$10.4M
est. pre-money
Reg A+ · Equity · Apr 2021

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Aug 30, 2021
Series A Super Voting Prefer · 0%COMMON · 100.0%
ClassOutstandingVotes / shareShare of totalLast price
Series A Super Voting Preferpreferred(as of Jun 22, 2021)10,000—0%—
COMMON348,018,019—100.0%—
Total348,028,019100%

Shares outstanding over timein today's share terms

348M174M0
Apr 2021Jul 2021
COMMONSeries A Super Voting Prefer

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Jan 17, 2023

  • as at September2,022 Common Shares100.0%of company
  • Harvey Larochelle29,926,786 shares6.67%of company
  • Wlaydyslaw Wojcik12,730,000 shares2.88%of company
  • Terry Kwan5,000,000 shares1.13%of company
  • Fawzia Afreen2,000,000 shares0.45%of company

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Apr 2021Closedvia DALMORE GROUP LLC
Raised $0 / $9MEst. pre-money $10.4M

Team

3 people
Peter Wojcik (1)
PHARMAGREEN BIOTECH INC . ( TRADING SYMBOL : PBHI) President, Secretary and Sole Director WFS PHARMAGREEN INC . ( A WHOLLY - OWNED SUBSIDIARY ) Chief Executive Officer, Secretary and Director 1155907 B . C . LTD . ( A WHOLLY - OWNED SUBSIDIARY ) Chief Executive Officer, Secretary and Director
Fawzia Afreen
WFS PHARMAGREEN INC . ( A WHOLLY - OWNED SUBSIDIARY ) Chief Operating Officer and Director
Terry Kwan
PHARMAGREEN BIOTECH INC . ( TRADING SYMBOL : PBHI) Principal Accounting Officer WFS PHARMAGREEN INC . ( A WHOLLY - OWNED SUBSIDIARY ) Chief Financial Officer and Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 10-QAug 14, 20230001477932-23-006115
    EDGAR
  • Form 10-QMay 19, 20230001477932-23-003779
    EDGAR
  • Form 10-QFeb 14, 20230001477932-23-000992
    EDGAR
  • Form 10-KJan 17, 20230001477932-23-000296
    EDGAR
  • Form 10-QAug 17, 20220001477932-22-006233
    EDGAR
  • Form 10-QMay 16, 20220001477932-22-003449
    EDGAR
  • Form 10-QFeb 22, 20220001477932-22-001005
    EDGAR
  • Form 10-KDec 29, 20210001477932-21-009538
    EDGAR
Source: SEC EDGARCIK 0001435181NVShare price $0.03Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.